BNP Paribas Financial Markets
LUCD icon

BNP Paribas Financial Markets’s Lucid Diagnostics LUCD Stock Holding History

BNP Paribas Financial Markets’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.2K Buy
22,625
+3,451
+18% +$3.72K ﹤0.01% 5191
2026
Q1 		$22.1K Sell
19,174
-3,702
-16% -$4.71K ﹤0.01% 5058
2025
Q4 		$24.9K Buy
22,876
+8,984
+65% +$10K ﹤0.01% 4959
2025
Q3 		$14K Buy
13,892
+8,001
+136% +$8.74K ﹤0.01% 4963
2025
Q2 		$6.78K Buy
+5,891
New +$7.61K ﹤0.01% 4924
2022
Q4 		– Sell
-973
Closed -$1.49K – 4360
2022
Q3 		$1.49K Buy
+973
New +$2.42K ﹤0.01% 4378

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BNP Paribas Financial Markets's LUCD Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Lucid Diagnostics (LUCD) stake by 18% in Q2 2026, buying an estimated $3.72K and bringing the position to 22,625 shares worth $24.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5191.

BNP Paribas Financial Markets first reported a position in LUCD in Q3 2022 and has held it in 6 quarters since. The position peaked at $24.9K in Q4 2025. 108 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • BNP Paribas Financial Markets held 22,625 shares of Lucid Diagnostics worth $24.2K as of Q2 2026.
  • BNP Paribas Financial Markets bought 3,451 Lucid Diagnostics shares in Q2 2026, an estimated $3.72K.
  • Lucid Diagnostics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5191 holding.
  • BNP Paribas Financial Markets first reported a position in Lucid Diagnostics in Q3 2022 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Lucid Diagnostics position peaked at $24.9K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.